Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib. By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
Dahse
R
R
HELIOS Clinics Erfurt, Institute of Pathology, Nordhauser Street 74, Erfurt 99089, Germany. rdahse@erfurt.helios-kliniken.de
Kosmehl
H
H
D000368:Aged; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000235:genetics; D018277:Carcinoma, Mucoepidermoid / Q000188:drug therapy / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005091:Exons; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010307:Parotid Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use
D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib